New anti-tuberculosis drugs and regimens: 2015 update

D'Ambrosio Lia, Centis Rosella, Sotgiu Giovanni, Pontali Emanuele, Spanevello Antonio, Migliori Giovanni Battista

Source: ERJ Open Res 2015
Journal Issue: May
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D'Ambrosio Lia, Centis Rosella, Sotgiu Giovanni, Pontali Emanuele, Spanevello Antonio, Migliori Giovanni Battista. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res 2015; 1: 00010-2015

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
New anti-tuberculosis drugs for special populations: a difficult-to-address issue
Source: Eur Respir J 2016; 48: 957-958
Year: 2016

Availability of anti-tuberculosis drugs in Europe
Source: Eur Respir J 2012; 40: 500-503
Year: 2012

Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007

New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005

Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance
Source: Eur Respir J 2012; 39: 802-804
Year: 2012

Availability of PCR for second-line drugs in Europe
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016

New and repurposed drugs for MDR-TB patients
Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence 
Year: 2017

Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy
Source: Eur Respir J 2012; 39: 1263-1266
Year: 2012

Novel drug regimens against MDR-TB
Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis
Year: 2016

Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe
Source: Eur Respir J, 58 (3) 2101196; 10.1183/13993003.01196-2021
Year: 2021

Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study
Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease
Year: 2021

New methodologogic approaches to the management of antituberculous service
Source: Eur Respir J 2003; 22: Suppl. 45, 381s
Year: 2003

Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey
Source: Eur Respir J 2015; 45: 1081-1088
Year: 2015

Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002

New and repurposed TB drugs use in children and adolescents with M/XDR-TB
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017

Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018

Facts and perspectives in the development of new anti-TB drugs
Source: Annual Congress 2008 - New insights into tuberculosis control
Year: 2008